Jazz Pharmaceuticals(JAZZ) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - Jazz Pharmaceuticals achieved record total revenue of $4.3 billion in 2025, reflecting a 5% growth over 2024, with fourth quarter revenue of $1.2 billion, representing a 10% year-over-year growth [4][30] - Non-GAAP adjusted net income for the full year 2025 was approximately $522 million, with non-GAAP adjusted EPS of $8.38 [30] Business Line Data and Key Metrics Changes - The rare sleep therapeutic area generated over $2 billion in total revenue in 2025, with XYWAV revenue growing 12% to approximately $1.7 billion for the year [11] - Epidiolex achieved blockbuster status with $1.1 billion in revenue, up 9% year-over-year, while Zepzelca generated $307 million in revenue in 2025, with a 15% year-over-year growth in the fourth quarter [14][20] - Modeyso generated $48 million in revenue from its launch in August 2025, indicating strong early performance [18] Market Data and Key Metrics Changes - XYWAV remains the number one branded treatment for narcolepsy and the only FDA-approved treatment for idiopathic hypersomnia (IH), with a 34% increase in net active IH patients in 2025 [12] - The introduction of two generic versions of high-sodium Xyrem is expected to negatively impact revenues, particularly in the second half of 2026 [13][31] Company Strategy and Development Direction - The company is sharpening its strategic focus on rare diseases, aiming to strengthen current franchises and expand into new areas, supported by a strong financial position [6][9] - Jazz Pharmaceuticals plans to leverage its proven track record in corporate development to continue building a more valuable company, with a focus on rare disease and oncology [8][38] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the future, highlighting the potential launch of zanidatamab in GEA and sustained execution for Modeyso and Zepzelca [9][38] - The company anticipates double-digit growth in rare oncology and epilepsy revenues in 2026, driven primarily by Epidiolex, Modeyso, and Ziihera [31] Other Important Information - The company resolved nearly all major litigation, including settling outstanding ANDA litigation for Epidiolex, which extends its runway into the late 2030s [5] - Jazz Pharmaceuticals sold its priority review voucher for $200 million, with half of the proceeds flowing to the company [8] Q&A Session Summary Question: Guidance around XYWAV for 2026 - Management indicated that XYWAV is expected to be flat or grow mid-single digits, with potential payer contracting concessions impacting guidance [40][42] Question: Hikma royalty rate and AG volume impact - Management noted a modest step down in the Hikma royalty rate for 2026, but significant economics will still flow to Jazz [49][50] Question: JZP047 background and development - JZP047 is a novel chemical entity developed in-house, focusing on absence epilepsy, with strong preclinical data supporting its development [53][54] Question: HER2 breast cancer population and potential uptake - Management highlighted approximately 150,000 patients with HER2-positive breast cancer, positioning zanidatamab as a potential treatment in the post HER2 setting [56][57] Question: Competitive pressure on XYWAV - Management expects minimal impact on XYWAV in the first half of 2026, with increasing competitive dynamics anticipated in the second half [65][66]